Bronchodilators Market

Market Overview:

The global bronchodilators market size reached US$ 37.6 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 55.9 Billion by 2032, exhibiting a growth rate (CAGR) of 4.4% during 2024-2032.

Bronchodilators are medications used to treat patients suffering from long-term conditions of narrow and inflamed airways, such as asthma, emphysema, and chronic obstructive pulmonary disease (COPD). They help relieve associated symptoms by relaxing the muscles around the airways or bronchi, clearing mucus from the lungs, and making breathing easier. They are available in the form of tablets, liquid, nebulizer solutions, and metered-dose and dry powder inhalers. Nowadays, bronchodilators are also utilized to enhance the effect of inhaled corticosteroids, which act as a primary treatment to reduce inflammation and prevent flare-ups in asthma.

Bronchodilators Market Trends:

A significantly rising number of patients with acute respiratory infections due to coronavirus disease (COVID-19) represents one of the key factors influencing the need for bronchodilators across the globe. Apart from this, increasing levels of air pollution, the rising number of smokers, and the growing prevalence of infectious diseases around the world are contributing to the risk of developing lung conditions. This is acting as another growth-inducing factor of the market. In addition, lung function declines gradually with age, which can make breathing slightly difficult. This, along with the increasing geriatric population and a considerable rise in consumer spending capacities, is driving the market. Other factors, such as improving healthcare infrastructure and diagnostic modalities and rising shift towards non-invasive procedures, are also propelling the market growth. Furthermore, several new classes of bronchodilators that can help overcome the limitations of existing products are in the preclinical phase stage. In confluence with this, health agencies of numerous countries are supporting research and development (R&D) activities for bronchodilators, which is anticipated to create a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global bronchodilators market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on indication, drug type and route of administration.

Breakup by Indication:

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Others
   

Breakup by Drug Type:

• Sympathomimetics
• Anticholinergics
• Phosphodiesterase Inhibitor
• Combination Drugs
   

Breakup by Route of Administration:

• Oral
• Injection
• Inhaler
   

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa
   

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sanofi, Teva Pharmaceutical Industries Ltd. and Vectura Group plc.

Report Coverage: